Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Breast 5Myeloid 4Lymphoid 4Gynecologic 4Other hematologic neoplasm 3Thoracic 2CNS 2Plasma cell 1Other neoplasm 1NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Ovarian Neoplasms 2565Uterine Cervical Neoplasms 1684Endometrial Neoplasms 1008Fallopian Tube Neoplasms 729Carcinoma, Ovarian Epithelial 680Breast Neoplasms 673Neoplasms 436Carcinoma, Non-Small-Cell Lung 377Colorectal Neoplasms 370Pancreatic Neoplasms 302Stomach Neoplasms 301Uterine Cervical Dysplasia 273Prostatic Neoplasms 261Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 214Peritoneal Neoplasms 197Carcinoma, Renal Cell 192Sarcoma 189Head and Neck Neoplasms 188Urinary Bladder Neoplasms 187Esophageal Neoplasms 186Recurrence 184Triple Negative Breast Neoplasms 179Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 166Colonic Neoplasms 162Papillomavirus Infections 152Small Cell Lung Carcinoma 126

Interventions

iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Hypersensitivity × Gynecologic × Clear all
NCT01837693 2025-06-26

NTCC2

Azienda USL Reggio Emilia - IRCCS

Phase NA Completed
41,127 enrolled
GynecologicOther neoplasm

Uterine Cervical Neoplasms, Hypersensitivity, Neoplasms, Precancerous Conditions

NCT01663753 2019-01-07

ERRICC

Hospices Civils de Lyon

Phase NA Completed
146 enrolled
Gynecologic

Uterine Cervical Neoplasms, Hypersensitivity

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
41 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
43 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡